News Releases

BIOMARK Closes First Tranche of Over-Subscribed Private
Placement Offering

2017, 29  JUNE

Vancouver, British Columbia – (June 29. 2017) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that further to its press release of May 9th, 2017, it has closed the first tranche of a non-brokered private placement for gross proceeds of $ 639,790.87 wherein BioMark issued 6,397,909 units at a price of $ 0.10 per unit. The Company anticipates closing another tranche within 4 weeks estimated around $ 470,000.00.

Each unit consists of one common share of BioMark and one-half of one share purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share of BioMark at $0.15 per share for a period of two years from the closing date of the private placement, subject to an acceleration clause. The Company will pay finders’ fees in accordance with CSE policies of a total of $ 21,600.00 and issue a total of 216,000 finders’ warrants where each Finders’ Warrant entitles the holder to acquire one share a price of $ 0.15 for a period of two years from the closing date of the private placement, subject to an acceleration clause.

The proceeds of the private placement will be used for the continuation of the company’s phase three clinical trials, regulatory submission costs, marketing initiatives and general working capital. The securities issued under the private placement will be subject to a hold period of four months and one day.

Press Release – Biomark Closes First Tranche of Private Placement Offering (PDF)

 

———————————————

BIOMARK Announces Private Placement

2017, 9 MAY

Vancouver, British Columbia – (May 9. 2017) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS:BMKDF) is pleased to announce a non-brokered Private Placement (the “Offering”). The Offering will be for up to 5,000,000 Units at a price of $0.10 to raise gross proceeds of up to $500,000.

.
Each Unit is composed of one common share (a “Share”) of the Company and one-half of a Share purchase warrant (a “Warrant”). Each whole Warrant shall entitle the holder to acquire one Share at a price of $0.15 per Share for a period of two years after the date of issuance. Finder’s fees may be payable. The private placement and finder’s fees are subject to regulatory approval.

.
The proceeds of the Offering will be used for the regulatory submission activities, further product development, marketing initiatives and general working capital. The securities in the private placement will be subject to a holding period of four months from the closing date of the private placement. Certain Insiders, Directors and Officers may subscribe for a portion of this placement. Closing of the private placement is subject to the Canadian Securities Exchange approval.

Press_Release_BIOMARK_ANNOUNCES_PRIVATE_PLACMENT_May_9th_2017 (PDF)

 

———————————————

BIOMARK Selected to Pitch at 2017 BCTECH Summit

2017, 16 MARCH

Vancouver, British Columbia – (March 16. 2017) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCQB: BMKDF) is proud to announce that was selected to pitch at #BCTECH Summit, during the Investment Showcase that was scheduled for March 15th 2017 at Vancouver Convention Centre.

President and CEO, Rashid Ahmed says, “BioMark is excited to be amongst the top selected companies to showcase our leading edge cancer diagnostic platform to a dynamic financial investment, government and biotechnology global community”.

About BCTECH Summit

The #BCTECH Summit is the largest technology conference in British Columbia showcasing the province’s vibrant technology industry. From innovations in eHealth data, autonomous vehicles and customer experience, to emerging ideas in cleantech, agritech and aerospace, the two-day event will give you the information and tools you need to move forward in a world where technology is impacting every part of our economy – and our lives.

The #BCTECH Summit brings together tech entrepreneurs, anchor companies, business leaders from traditional industries, investors, government and academia to establish new connections, nurture existing networks, and exchange fresh ideas around innovation driving business growth.

More about the summit is available at http://bctechsummit.ca/

News Release – BIOMARK Selected To Pitch At BCTech Summit 2017 (PDF)

 

———————————————

Biomark Announces Grant Funded Partnership With TMIC

2015, 2 MARCH

BIOMARK ANNOUNCES GRANT FUNDED PARTNERSHIP WITH TMIC (PDF)

 

———————————————

BioMark Engages Stockhouse.com Deal Room with Private Placement

2016, 20 JUNE

F1-Press_Release_-_Engage_Stock_House_Deal_Room_-_June_2016 (PDF)

 

———————————————

BioMark Announces Private Placement Offering

2016, 9 MARCH

Press Release – Biomark Announces Private Placement-March 9 2016 (PDF)

 

———————————————

BioMark Closes First Tranche Of Private Placement Offering

2016, 15 MARCH

Press Release – Biomark Closes Partial Private Placement-March 15th 2016 (PDF)

 

———————————————

BioMark Diagnostics to Conduct Validation Studies for its Patented Assays in Patients with Lung Cancer

Dr. James Bond of Surrey Memorial Hospital to act as Principal Investigator

2015, 10 SEPTEMBER

BioMark Diagnostics to Conduct Validation Studies (PDF)

 

———————————————

BioMark Diagnostics to Present at Rodman & Renshaw Global Investment Conference

2015, 3 SEPTEMBER

BioMark Diagnostics to Present at Rodman & Renshaw Global Investment Conference (PDF)

 

———————————————

BioMark Diagnostics Unveils U.S. Strategy

2015, 13 AUGUST

Biomark US Strategy (PDF)

 

———————————————

BioMark Appoints Dr. Thomas Malcolm to Lead U.S. Operations

2015, 11 AUGUST

BioMark Appoints Dr. Thomas Malcolm to Lead U.S. Operations (PDF)

 

———————————————

BioMark Diagnostics Engages LHA for Investors Relations

2015, 29 JUNE

BioMark Engages LHA (PDF)

 

———————————————

BioMark Receives No Objection Letter From Health Canada

2015, 26 MAY

BioMark Receives No Objection Letter From Health Canada (PDF)

 

———————————————

BioMark Presents At 11th Annual Conference of the Metabolomics Society

2015, 14 APRIL

BioMark Presents At 11th Annual Conference of the Metabolomics Society (PDF)

———————————————

BioMark Receives BIAP funding from NRC-IRAP

2015, 31 MARCH

BioMark Receives BIAP funding from NRC-IRAP (PDF)

———————————————

BioMark Added To Cse Composite Index

2015, 25 MARCH

BIOMARK_ADDED_TO_CSE_COMPOSITE_INDEX_ (PDF)

———————————————

Biomark Announces A Final Closing Private Placement

2015, 18 FEBRUARY

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES

Press Release – Closing_Private Placement_release_-_February 2015 (PDF)

 

———————————————

BioMark To Be On CBC Early Edition

2015, 14 JANUARY

Press Release – BIOMARK TO BE ON CBC EARLY EDITION (PDF)

 

———————————————

Biomark Announces A Partial Closing Private Placement

2015, 2nd JANUARY

Press Release-BIOMARK ANNOUNCES A PARTIAL CLOSING PRIVATE PLACEMENT-January 2, 2015 (PDF)

 

———————————————

BioMark Diagnostics, Inc. to present at the inaugural equities.com Small-Cap Stars Conference at the NASDAQ MarketSite on December 18, 2014

2014, 16th DECEMBER

NASDAQ MarketSite (PDF)

 

———————————————

BioMark Receives Health Canada Protocol Approval

2014, 8th DECEMBER

Press Release – BioMark Receives Health Canada Protocol Approval (PDF)

 

———————————————

BioMark Records First Revenues

2014, 4th DECEMBER

Press Release BIOMARK RECORDS FIRST REVENUES – December 4 2014-F (PDF)

 

———————————————

Dr. Safieddin Safavi-Naeini Joins Biomark Scientific Advisory Team

2014, 2 DECEMBER

Dr. SAFIEDDIN SAFAVI-NAEINI JOINS BIOMARK SCIENTIFIC ADVISORY TEAM (PDF)

 

———————————————

BioMark AGM September 17, 2015


BioMark is holding its Annual General and Special Meeting on September 17, 2015 at 925 W Georgia Street #1820, Vancouver, BC. We look forward to seeing you at the meeting. For more information, please visit SEDAR

Download AGM materials

Form of Proxy (PDF)

Notice of Meeting (PDF)

Management Information Circular (PDF)

BIOMARK Appoints Ms. Guoyu Huang As Interim CFO

2017, 19 JUNE

 

Press Release – BIOMARK APPIONTS MS GUOYU HUANG AS INTERIM CFO (PDF)

———————————————

BIOMARK Closes Previous Announced Private Placement Offering

2017, 8 MAY

Press_Release_-_Biomark_Closes_Private_Placement_announced_on_June_24_2016 (PDF)

 

———————————————

BIOMARK Invited to Project Pitch Stage For GAPP Application

2017, 20 FEBRUARY

News Release – BIOMARK’s GAPP Success (PDF)

 

———————————————

BioMark Completes Data Collection And Submits Data for Analysis prior to Health Canada Submission

2016, 5 JULY

BioMark Announce Progress Towards Data Analysis  (PDF)

 

———————————————

Biomark Receives Approval For Its Lung Cancer Treatment Protocol

2016, 29 MARCH

Press Release – BUX – Expansion of Cancer Platform (PDF)

 

———————————————

BioMark Announces Progress Towards Data Analysis

2016, 16 FEBRUARY

BioMark Announce Progress Towards Data Analysis (PDF)

 

———————————————

BioMark Diagnostics Receives Clearance from Health Canada to Commence Clinical Trial with Patented Non-Invasive, Urine-Based Assay to Measure Response to Treatment for Lung Cancer

2015, 9 SEPTEMBER

Sept 9thBioMark Diagnostics Receives Clearance from Health Canada (PDF)

 

———————————————

BioMark Closes Second Tranche of Private Placement Offering

2016, 24 JUNE

F-Press_Release_-_Second_Tranche_Private_Placement_-_$0_15_units_-_June_2016 (PDF)

 

———————————————

BioMark Diagnostics Announces Progress in Assay Validation for Clinical Sample Analysis

2015, 19 AUGUST

BioMark Diagnostics Announces Progress in Assay Validation for Clinical Sample Analysis_1 (PDF)

 

———————————————

BioMark Diagnostics-Sponsored Project Receives NSERC Engage Grant

2015, 29 JULY

BioMark Diagnostics-Sponsored Project Receives NSERC Engage Grant (PDF)

 

———————————————

Biomark Secures DTC Eligibility

2015, 28 MAY

Press Release – BIOMARK SECURES DTC ELIGIBILITY (PDF)

 

———————————————

BIOMARK’s Clinical Technology Center at Innovation Boulevard in Surrey BC

2015, 27 APRIL

Press Release – BIOMARK’s New Office Site at Innovation Boulevard (PDF)

 

———————————————

BioMark Receives NSERC Engage Grant for Raman Enhancement with Dr. SAFIEDDIN SAFAVI-NAEINI

2015, 7 APRIL

BioMark Receives NSERC Engage Grant (PDF)

 

———————————————

BioMark Receives the Commercialization Support for Business (CSB) Stream 1 Program

2014, 25 NOVEMBER

Press Release BioMark Receives the Commercialization Support for Business (CSB) Stream 1 Program (PDF)

 

————————————————-

Dr. John Yoo Joins BioMark Advisory Team

2014, 17 NOVEMBER

Dr. JOHN YOO JOINS BIOMARK ADVISORY TEAM – November 17, 2014 (PDF)

————————————————-

BioMark Announces Appointment of Bill Good

2014, 12 November

BIOMARK_ANNOUNCES_APPOINTMENT_OF_BILL_GOOD (PDF)

————————————————-

BioMark Expands Phase 3 Clinical Trials

2014, 5 NOVEMBER

BIOMARK_DIAGNOSTICS_INC_EXPANDS_PHASE_3_CLINICAL_TRIALS (PDF)

————————————————-

BioMark Approved Listing and Commences Trading on the CSE

2014, 3 NOVEMBER

 

Biomark_Approved_for_Listing_and_Commences_Trading_on_the_CSE (PDF)

————————————————-

BioMark Raman SenSers Product Launch at Strategies on Biophotonics Boston September 9-11 2014

http://pubs.rsc.org/en/Content/ArticleLanding/2014/AN/c4an01309c#!divAbstract

BioMark Announces Partnership With The Metabolomics Innovation Centre

2015, 27 MARCH

 

BIOMARK_ANNOUNCES_PARTNERSHIP_WITH_THE_METABOLOMICS_INNOVATION_CENTRE (PDF)

———————————————

BioMark Announces OTCQB Listing

2015, FEBRUARY 17

Press release – BIOMARK ANNOUNCES OTCQB LISTING- February 17th (PDF)

 

———————————————

BioMark Receives US Trading Symbol BMKDF from FINRA and Commences Trading in the USA

2015, 14 JANUARY

 

Press Release – BioMark Receives US Trading Symbol BMKDF (PDF)

 

———————————————

BioMark Lists on Frankfurt Stock Exchange

2014, 26th NOVEMBER

Press Release BIOMARK LISTS ON FRANKFURT STOCK EXCHANGE – November 26, 2014 (PDF)

———————————————